Seòmar agus comataidhean

The SPIRE Multi-morbidity local report has the following Respiratory Conditions

•Patients with currently treated asthma

•Patients with Bronchiectasis

•Patients with chronic obstructive pulmonary disease

This is a local report which sits within local GP IT systems, and it is for practices to manage this information themselves.

The Scottish Government is committed to supporting the vital role of Scottish Hospices. In June 2020, we provided £10.1m in emergency funding to hospices to meet in full their funding requests for loss of income during the first lockdown period.

On the 24 March 2021, we confirmed that an additional £16.9m will be provided to Scottish Hospices to fully meet their requests for support relating to loss of income during the most recent lockdown. As such, the total funding allocated to hospices to support their work during the pandemic in the financial year 2020-2021 is approximately £27m. The breakdown of payments can be viewed in the following table.

Thank you for your Parliamentary Question asking how many people have been prescribed (a) Erenumab and (b) Fremanezumab for migraine treatment since Scottish Medicine Consortium approval was granted.

The Scottish Medicine Consortium granted approval for Erenumab and Fremanezumab for migrane treatment on the 8th April 2019 and 13th January 2020, respectively.

Information on the total number of patients who have been prescribed Erenumab and Fremanezumab is not available centrally.

Erenumab is prescribed in both primary care and secondary care and Fremanezumab is used in secondary care only. Patient information is not recorded in the secondary care prescribing dataset (the Hospital Medicines Utilisation Database (HMUD)) and as a result it is not possible to provide patient counts for Erenumab or Fremanezumab in secondary care.

The current licence to operate, between Scottish Government Ministers and the Scottish Exhibition Campus (SEC) for the NHS Louisa Jordan Hospital, established to support Scotland’s response to the Coronavirus (COVID-19) pandemic, is due to end on 31 March 2021 and will not be extended. The Mass Vaccination Centre which is currently operating in NHS Louisa Jordan will be relocated to The SSE Hydro with no gaps in provision. More information can be found in the Scottish Government Press Release dated 18 March 2021

https://www.gov.scot/news/nhs-louisa-jordan-to-close/

Forensic toxicology services are currently provided by the University of Glasgow under a contract with COPFS. COPFS has agreed a contract extension with the University of Glasgow to 31 March 2022 to facilitate transfer of service provision to another provider.

As part of the process aimed at improving the delivery of toxicology services, the University of Glasgow agreed an Improvement Plan with COPFS which sets out performance targets and requires the University to provide data on a weekly basis to COPFS on the progress of their outstanding cases. The current work in progress is ahead of the Improvement Plan target and the level of work in progress has reduced significantly since June 2020. There are seven outstanding 2020 cases and these will be completed shortly. The average turnaround time is currently 48 days.

COPFS has identified a new provider of toxicology services and detailed transition planning work is being undertaken by this provider with a view to the service transitioning to them at the cessation of the University of Glasgow contract. COPFS and the University of Glasgow have agreed to work together to assist the new provider to manage that transition effectively.

Public Health Scotland provide regular reports which include suspected drug-related deaths, to help maintain and improve the quality of care and support available to people who use drugs. That data is closely examined by Public Health Scotland and key partner organisations, particularly any notable increases in suspected deaths such as those noted in December 2020. There can be a number of reasons for spikes in the number of deaths being recorded, but at this stage no specific causes or geographical links have been identified to explain this particular increase. We continue to work closely with partners to monitor these figures and any arising concerns.

The official, confirmed, drug deaths statistics for 2020 will be published by National Records of Scotland in the summer. Whilst there were significant concerns about the potential impact of the pandemic on vulnerable groups, including those who used drugs, a range of work was undertaken by Scottish Government, with significant investment made, to mitigate these risks. At this stage we do not have any clear evidence to suggest that the total number of confirmed drug-related deaths in 2020 will surpass the numbers recorded in 2019.

According to Rape Crisis Scotland, as of October 2019 and October 2020 waiting list times for each centre were as follows:

The SPIRE ‘Respiratory search’ report is currently on hold, however it should be noted that this is a local report which sits within local GP IT systems and would allow GPs/Practice Managers only to see the data for their patients.

We are continuing to work with sportscotland to continually review and establish the needs of the sector. For leisure centres which are owned by the public sector, the Scottish Government and COSLA have now finalised a lost income scheme, including support for ALEOS worth £200 million. Taken together with the £49 million previously announced the total support for lost income is now potentially £249 million. The Scottish Government are also committed to passing on any additional UK Government consequentials for lost income, in full to local government. However, it is the responsibility of individual local authorities to manage their own budgets and to allocate the total financial resources available to them on the basis of local needs and priorities.

Since the start of the Covid-19 outbreak the Scottish Government has worked closely with the UK Government and private and public sector partners to develop a range of support mechanisms for businesses. Information on all available support for businesses can be found on Find Business Support . The website is regularly updated with information on any new support packages or changes to existing ones.

The original specification for this report was for Patients fully registered of all ages with a coded diagnosis of asthma (and no more recent code of asthma resolved) who:

Have had one or more hospital admissions or A&E attendances with asthma in the previous year

OR

Have ordered 6 or more ‘short acting beta agonist’ inhalers in the previous year

OR

Have ordered 6 or less steroid containing inhalers in the previous year

OR

Have had 2 or more asthma exacerbations in the previous year (prescription for oral steroids)

AND

Have not had an asthma review within the previous year

This is a local report which sites within local GP IT systems, and it is for practices to manage this information themselves.